WHO vaccine-preventable diseases: monitoring system. 2016 global summary

Last updated 27-May-2016 (Data received as of 20-May-2016)
Next overall update Fall 2016
2015 data are provisionary
EPI mother and child logo         
Select a country

Development status: Developing GNI / capita (US$): 14'5401 Infant (under 12 months) mortality rate: 82
GDP / capita (US$): 22'7331 Child (under 5 years) mortality rate: 112

Population data in thousands3

  2015  2014  2013  2012  2011  2000  1990  1980 
Total population 56  55  54  54  53  46  41  43 
Surviving infants
Pop. less than 5 years
Pop. less than 15 years 14  14  14  14  14  14  13  16 
Female 15-49 years 14  14  14  14  14  12  10  11 

Number of reported cases

(Click for retrospective incidence data for Saint Kitts and Nevis)
Diphtheria
ChartChart
 
Japanese encephalitis
ChartChart
 
Measles
ChartChart
  80  305 
Mumps
ChartChart
 
Pertussis
ChartChart
 
Polio*
ChartChart
 
Rubella
ChartChart
 
Rubella (CRS)
ChartChart
 
Tetanus (neonatal)
ChartChart
 
Tetanus (total)**
ChartChart
 
Yellow fever
ChartChart
 
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For desagregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Saint Kitts and Nevis)
Vaccine year result method % card seen                                                
BCG          95  99  94  95  99  99* 
DTP1          92  99  84  96  97  99* 
DTP3          94  98  97  99*  98  99  99*  56 
DTP4          85  97 
IPV1          99* 
HepB_BD          99* 
HepB3          94  98  97  99*  98  99* 
Hib3          94  98  97  99*  98  12 
JapEnc         
MCV1          95  93  99  95  99*  99*  99* 
MCV2          90  90  94  90  99*  99 
PCV1         
PCV3         
Pol3          91  96  97  99*  99  99  99*  76 
Rota1         
RotaC         
Rubella1          95  93  99  95  99* 
TT2plus         
PAB         
VAD1         
YFV         
° indicates that more than 1 survey occurred that year.  * indicates the country reported above 100% coverage.

  Next update: Mid July 2016

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Saint Kitts and Nevis)
BCG
ChartChart
  99  94  95  99  99  80 
DTP1
ChartChart
  99  99  99  99  99  99  79 
DTP3
ChartChart
  97  96  97  97  98  99  56 
HepB3
ChartChart
  98  97  98  98  99 
HepB_BD
ChartChart
 
Hib3
ChartChart
  98  97  98  98  12 
MCV1
ChartChart
  93  99  95  99  99  99 
MCV2
ChartChart
  90  94  90  99  99 
PCV3
ChartChart
 
Pol3
ChartChart
  93  96  97  98  98  99  76 
RotaC
ChartChart
 

Number of districts in the country 17  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
100 
   
/
|
|
\
Greater or equal to 90% 76
From 80 to 89% 12
From 50 to 79% 12
Less than 50% 0
Proportion of districts
not reporting DTP3 coverage
0
DTP3 reported coverageDTP3 reported coverage

Immunization Schedule (2015 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG 0-4 weeks; Yes
DTwP 3, 4, 5, 18 months; 4-5 years; Yes
DTwPHibHepB 2, 4, 6 months; Yes
HepB_Adult 1st contact; +4 weeks; +7 months; Yes
HepB_Pediatric birth; From October 2015
IPV 2, 4, 6, 18 months; 4-5, 16 years special groups
MMR 1, 2 years; Yes
OPV 2, 4, 6, 18 months; 4-5, 16 years; Yes
Td 11, 16, >26 years; Yes
YF Yes travelers to endemic countries

Immunizaton indicators

Indicator Expected answer 2015  2014  2013  2012  2011  2010  2009 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR Yes  Yes  Yes  Yes  No  Yes  No 
What years does the MYP cover? number 2'015    2010-2011      2'010   
Nº of districts with microplans that include activities to raise immunization coverage number 17  17  17  17  17  17  17 

System performance

Total Nº districts in country number 17  17  17  17  17  17  17 
Nº districts with DTP3 coverage >=80% number 17  16  17  17  17  17  14 
% of districts with DTP3 coverage >=80% From 0 to 100% 100  94  100  100  100  100  82 
Nº districts with measles (MCV1) coverage >=95% number 11  12  13  17  17  17  14 
% of districts with MCV1 coverage >=95% From 0 to 100% 65  71  76  100  100  100  82 

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND Yes  No  Yes  Yes  Yes     
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes    Yes    Yes  Yes  Yes 

Finance

Immunization expenditure financed, using Government funds? From 0 to 100% 95  100  100  100  100  100  100 

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR No  No  No  No  No     

Sources

 1  "The 2013 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2013, data for 2012
 3  "United Nations, Population Division. The World Population Prospects - the 2015 revision". New York, 2016.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.